Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Pexidartinib hydrochloride by Daiichi Sankyo for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma): Likelihood of Approval
Pexidartinib hydrochloride is under clinical development by Daiichi Sankyo and currently in Phase II for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)....
Data Insights
Pexidartinib hydrochloride by Daiichi Sankyo for Sarcomas: Likelihood of Approval
Pexidartinib hydrochloride is under clinical development by Daiichi Sankyo and currently in Phase II for Sarcomas. According to GlobalData, Phase...